Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1)
Связь структуры с активностью нового ряда ингибиторов опухолевого транспортера 1-го типа для L-аминокислот (LAT1)
2017-02-01
SCID: 54.1/bxfjnuf5
Discuss with AI
L-type amino acid transporter 1 (LAT1)LAT1 inhibitorsSKN103mTOR activitystructure-activity relationship
Figures from the paper
Abstract (AI)
L-type amino acid transporter 1 (LAT1) is known as a cancer-type amino acid transporter. In cancer cells, LAT1 is responsible for the cellular uptake of many essential amino acids including leucine that activates mechanistic/mammalian target of rapamycin (mTOR), regulating cancer cell growth. In this study, we designed a novel series of LAT1 inhibitors, SKN101–105, based on the structure of triiodothyronine (T3), a known LAT1 blocker. The compounds consist of core structure of 2-amino-3-[3,5-dichloro-4-(naphthalene-1-methoxy)-phenyl]-propanoic acid and different modifications on the naphthalene. Among them, the compounds including SKN103 with a modified phenyl group at C-7 position of naphthalene inhibited LAT1-mediated leucine transport, whereas SKN102 with a phenyl group at C-6 position did not, indicating the importance of the position of substituents on the naphthalene for the interaction with LAT1. SKN103 was suggested to be a non-transportable blocker rather than a substrate of LAT1 and inhibited LAT1 in a competitive manner with the Ki value of 2.1 μM. SKN103 suppressed mTOR activity and the growth of cancer cells. Moreover, SKN103 in combination with cisplatin additively enhanced the growth inhibition in cancer cells. This study provides an additional insight into the structure-activity relationship of LAT1 ligands, which could lead to designing desirable LAT1 inhibitors.
Key Findings
1
A novel series of LAT1 inhibitors, SKN101–105, was designed using the structure of the known LAT1 blocker triiodothyronine (T3).
2
Combining SKN103 with cisplatin additively enhanced growth inhibition in cancer cells.
3
SKN103 acted as a non-transportable, competitive LAT1 blocker with a Ki value of 2.1 μM rather than as a LAT1 substrate.
4
SKN103 suppressed mTOR activity and cancer-cell growth, consistent with inhibition of LAT1-mediated leucine uptake.
5
Substituent position on the naphthalene ring determined LAT1 inhibition: C-7 phenyl substitution in SKN103 was active, whereas C-6 substitution in SKN102 was inactive.
Research Object
LAT1 inhibitors SKN101–105 and LAT1-mediated amino acid transport in cancer cells
Research Subject
Structure–activity relationships, transport inhibition, substrate/blocker behavior, and anticancer effects of the novel LAT1 inhibitors, particularly SKN103
Publication Details
Publication Date
2017-02-01
Journal
Publisher
ISSN
Cited by
80
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A12016
Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ^|^alpha;-Alkyl Moieties2012
Cited by7
The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health2018
The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer2019
Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment2020
ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation2021
Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods2018
Chemical Approaches for Studying the Biology and Pharmacology of Membrane Transporters: The Histidine/Large Amino Acid Transporter SLC7A5 as a Benchmark2021
Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT12018